Evaluating advanced radiotherapy techniques for prostate cancer
Efficacy of Advanced Radiotherapy (ART) in Prostate Cancer Patients With Early Stage, Advanced, Metastatic and Relapsed Disease (PROST-ART)
This study is testing different advanced radiation treatments for prostate cancer to see how well they work and how they affect patients' lives.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2500 (estimated) |
| Ages | 18 Years to 95 Years |
| Sex | Male |
| Sponsor | IRCCS San Raffaele Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT06546267 on ClinicalTrials.gov |
What this trial studies
This observational study analyzes the outcomes of various advanced radiotherapy techniques, including Image Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), and Stereotactic Body Radiotherapy (SBRT), in patients with different stages of prostate cancer. The study focuses on patients treated between 2004 and 2024, assessing their biochemical relapse-free survival, local and regional relapse rates, and overall survival. Additionally, it evaluates the acute and late toxicity of these treatments and includes a quality of life survey for participants who consent. The study aims to provide insights into the efficacy and safety of these advanced radiotherapy approaches.
Who should consider this trial
Good fit: Ideal candidates are prostate cancer patients over 18 years old who have undergone advanced radiotherapy techniques.
Not a fit: Patients with other tumors or those over 95 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve treatment strategies and outcomes for patients with prostate cancer.
How similar studies have performed: Other studies have shown promising results with advanced radiotherapy techniques, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Prostate cancer patients, \> 18 years old, treated with IGRT, IMRT, SBRT Exclusion Criteria: * other tumors * \> 95 years old
Where this trial is running
Milan
- IRCCS San Raffaele Scientific Institute — Milan, Italy (Recruiting)
Study contacts
- Principal investigator: Nadia G Di Muzio, Prof — IRCCS San Raffaele, Milan
- Study coordinator: Andrei Fodor, MD
- Email: fodor.andrei@hsr.it
- Phone: +39-0226437634
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.